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Background and aims. Bile acids (BAs) are signaling molecules involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). BAs can modulate both glucose and lipid metabolism in insulin resistance (IR), a major pathogenic mechanism for the progression to non-alcoholic steatohepatitis (NASH). However, the association between BA composition and insulin sensitivity (IS)/IR has been not fully investigated yet. We aimed to assess the relationship between BA composition and sites and mechanisms of IR in non-diabetic NAFLD patients.

Methods. 41 patients with biopsy-proven NAFLD were studied. Plasma BA composition was assessed by GC-MS. Adipose tissue IR (AT-IR), Hepatic IR (Hep-IR) and glucose clearance (GC) were derived from tracer studies.  Visceral fat (VF) was assessed by NMR. Liver histology was scored according to Kleiner. 
Results. Plasma levels of total primary BAs correlated with waist circumference (WC) (r=0.378, p=0.014), VF (r=0.406, p=0.023,) and fasting C-peptide (C-pep) (r=0.301, p=0.056,), while secondary BAs showed no correlation with anthropometric/metabolic parameters. Among primary BAs, GCA directly related to visceral adiposity and AT-IR while TCDCA was associated with visceral adiposity (WC and VF), insulin secretion (C-pep), IR in adipose tissue (AT-IR), liver (Hep-IR) as well as with hepatic steatosis and inversely related to muscle IS (GC) (Table 1). UDCA had no correlation with metabolic parameters while TUDCA (hydroxylated) was significantly correlated with visceral adiposity, IR at different sites and liver fat (Table 1). 
Conclusions. In NAFLD patients, GCA, TCDCA and TUDCA are increased proportionally to IR at the main sites of insulin action (adipose tissue, liver and muscle) irrespective of diabetes. Since TCDCA is the most potent endogenous agonist of FXR, which upon activation improves insulin sensitivity, and TUDCA treatment in obese individuals has been found to improve insulin sensitivity, these increases may represent compensatory mechanisms to IR.
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Taurochenodeoxycholic acid (TCDCA)	r	0.334	0.349	- 0.304	0.505	0.429	0.439	0.331	0.393
	p 	0.033	0.050	0.050	0.001	0.007	0.006	0.042	0.014
Taurodeoxycholic acid (TUDCA)	r	0.339	0.209	-0.151	0.390	0.474	0.482	0.467	0.374
	p 	0.030	0.258	0.347	0.012	0.002	0.001	0.002	0.016


